{
  "catalogId": "aae02d5b-c15d-4234-825c-df089c705fd8",
  "name": "GLIVEC ® 100 MG",
  "status": "draft",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "129 91 30789 01",
  "treatmentDescriptions": "Glivec is indicated for the treatment of adult patients and children 3 years of age and above with Ph+ chronic myeloid leukaemia (Ph+ -CML) in chronic phase  accelerated phase or blast crisis. Glivec is also indicated for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).   Glivec is also indicated for the treament of :   * Adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. * Adult patients with relapsed or refractory Ph + ALL as monotherapy.   * Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.   * Adult patients with myelodyspiastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet - derived growth factor receptor ) gene re- arrangements.   * Adult patients with hypereosinophilic syndrome (HES) and/or  chronic eosinophilic leukaemia (CEL) who have the FIP1L1- PDGFRalfa fusion kinase (mutational analysis or FISH demonstration for CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR alfa fusion kinase negative.  * Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-kit mutation. * Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.",
  "termsOfIssue": "Prescription required",
  "form": "film coated tablets",
  "route": "per os",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "IMATINIB AS MESYLATE",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L01XX28",
      "name": "IMATINIB"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת ",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "GLIVEC 100MG 60 FCTAB",
      "manufacturer": {
        "name": "נוברטיס פארמה",
        "countryOfOrigin": "IL"
      },
      "strength": [
        {
          "value": 100.0,
          "unit": "mg"
        }
      ],
      "quantity": {
        "value": 60.0,
        "unit": "units"
      },
      "packagingDescription": "BLISTER PVC",
      "shelfLife": "24",
      "storageConditions": "",
      "codes": {
        "moh": "4854",
        "yarpa": "62801",
        "pharmasoft": "7708"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 2830.2041,
        "retailMargin": 10.0,
        "maxRetailPrice": 3113.22451,
        "maxPriceWithVAT": 3673.604922
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-08-01T17:51:43.321828",
    "tags": [],
    "smartValidation": {
      "extractedFrom": "GLIVEC 100MG 60 FCTAB",
      "processedBy": "smart_validation",
      "matchScore": 0.8083333333333333,
      "status": "corrected",
      "correctedAt": "2025-08-01T17:51:43.321838",
      "previousRegistration": "129 92 30790 00",
      "newRegistration": "129 91 30789 01",
      "apiSource": "GLIVEC ® 100 MG"
    }
  },
  "nameHebrew": "גליבק ® 100 מ\"ג",
  "registrationDate": "2023-12-31"
}